Skip to content

Press Releases are sponsored content and not a part of Finbold's editorial content. For a full disclaimer, please click here. If you encounter any issues, kindly report them to [email protected]. Crypto assets/products can be highly risky. Never invest unless you’re prepared to lose all the money you invest.

Injective Skyrockets Following OKX Listing; InQubeta Rallies, Raising $6.3M in Presale

Press Releases

The final quarter of 2023 has seen Injective (INJ) make headlines on several occasions. This time around, it is making waves for its recent OKX listing. This development improved exposure to the token, skyrocketing in the process.

Another token stirring up excitement is InQubeta (QUBE). Its ongoing presale has become the talk of the crypto community, and it recently raised $6.3 million in funds.

This post will discuss this remarkable development in the Injective ecosystem. Further, it will cover the rising popularity of InQubeta, explaining why it is one of the best coins to invest in. Let’s begin.

InQubeta (QUBE): Millions of Dollars Raised in Presale

In less than a week, InQubeta (QUBE) added over $500,000 to its fundraising, which is now more than $6.3 million. The rising popularity of this top ICO is because of the problem it aims to solve and its significant upside potential.

It will become the first crowdfunding platform for AI startups through cryptocurrency. This forward-thinking approach will help it solve the fundraising challenge in the AI sector. By minting investment opportunities, startups can source funds. These investment opportunities will be in the form of equity-based NFTs and will be offered to investors.

Through its intriguing model, AI startups will be able to raise funds by giving up stakes in their projects. In addition, it also aims to make the promising AI market accessible to investors. It will achieve this by introducing a fractional investment model and employing NFTs.

Other key appeals of the token include its deflationary nature and governance function. As a deflationary token, its supply will constantly decrease, which will result in the price climbing in value. As a governance token, holders will have a say in its future.

The presale is in its sixth stage, and a token costs only $0.01925. According to analysts, the price will rise by 60x, which makes it the best new crypto to invest in.

Injective (INJ): OKX Listing

Injective (INJ) stands out in the crypto space for the crucial role it plays in the DeFi (decentralized finance) space. Its explosive growth in the second half of 2023 saw it become one of the top crypto coins.

As one of the top defi projects, its functions involve powering exchanges, dApps (decentralized applications), and loan protocols. This makes it a major player in the crypto space, particularly in the DeFi world.

Recently, on November 30, OKX, a top exchange, added support for Injective. This created excitement, and more liquidity flowed into the token, resulting in a price upswing.

However, since then, Injective appears to be consolidating. According to analysts, it is taking a breather following the significant price surge. In the past three months, the price of INJ rose by over 100%.

Its current consolidation suggests an impending bull run, making it a good crypto to buy.

Conclusion

Injective has been gaining traction on all fronts. The latest is its listing by OKX, a crypto exchange. This initially pushed up its value, but it has been in a consolidation phase of late. Meanwhile, InQubeta has become the top ICO of 2023, raising more than $6.3 million. It is primed for a 60x rally, which makes it one of the tokens to watch out for.

Visit InQubeta Presale 

Join The InQubeta Communities

Disclaimer

This post is sponsored. Finbold neither endorses nor takes responsibility for the accuracy, quality, advertising, products, or other materials on this page. Readers are strongly encouraged to perform their own research before making any decisions regarding the company. Finbold will not be held accountable, either directly or indirectly, for any harm or loss that may stem from or be linked to the usage or reliance on any information, goods, or services mentioned on the page.